ES2671516T3 - Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno - Google Patents

Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno Download PDF

Info

Publication number
ES2671516T3
ES2671516T3 ES14708992.4T ES14708992T ES2671516T3 ES 2671516 T3 ES2671516 T3 ES 2671516T3 ES 14708992 T ES14708992 T ES 14708992T ES 2671516 T3 ES2671516 T3 ES 2671516T3
Authority
ES
Spain
Prior art keywords
carbon atoms
alkyl
hydrogen
substituted
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14708992.4T
Other languages
English (en)
Spanish (es)
Inventor
Heather Elizabeth BURKS
Michael A. DECHANTSREITER
Guo He
Jill NUNEZ
Stefan Peukert
Clayton SPRINGER
Yingchuan Sun
Noel Marie-France THOMSEN
George Scott Tria
Bing Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2671516T3 publication Critical patent/ES2671516T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/64—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES14708992.4T 2013-02-19 2014-02-12 Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno Active ES2671516T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361766439P 2013-02-19 2013-02-19
US201361766439P 2013-02-19
PCT/US2014/015938 WO2014130310A1 (en) 2013-02-19 2014-02-12 Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders

Publications (1)

Publication Number Publication Date
ES2671516T3 true ES2671516T3 (es) 2018-06-06

Family

ID=50239942

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14708992.4T Active ES2671516T3 (es) 2013-02-19 2014-02-12 Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno

Country Status (46)

Country Link
US (5) US8877801B2 (cg-RX-API-DMAC7.html)
EP (2) EP3360870A1 (cg-RX-API-DMAC7.html)
JP (1) JP6364028B2 (cg-RX-API-DMAC7.html)
KR (1) KR102279999B1 (cg-RX-API-DMAC7.html)
CN (1) CN105008343B (cg-RX-API-DMAC7.html)
AP (1) AP2015008618A0 (cg-RX-API-DMAC7.html)
AR (1) AR094704A1 (cg-RX-API-DMAC7.html)
AU (1) AU2014219283C1 (cg-RX-API-DMAC7.html)
BR (1) BR112015018882B1 (cg-RX-API-DMAC7.html)
CA (1) CA2899030C (cg-RX-API-DMAC7.html)
CL (1) CL2015002098A1 (cg-RX-API-DMAC7.html)
CR (1) CR20150424A (cg-RX-API-DMAC7.html)
CU (1) CU24337B1 (cg-RX-API-DMAC7.html)
CY (1) CY1120155T1 (cg-RX-API-DMAC7.html)
DK (1) DK2958907T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2015000202A (cg-RX-API-DMAC7.html)
EA (1) EA028032B1 (cg-RX-API-DMAC7.html)
ES (1) ES2671516T3 (cg-RX-API-DMAC7.html)
GE (1) GEP201706638B (cg-RX-API-DMAC7.html)
GT (1) GT201500233A (cg-RX-API-DMAC7.html)
HK (1) HK1251227A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20180816T1 (cg-RX-API-DMAC7.html)
HU (1) HUE039052T2 (cg-RX-API-DMAC7.html)
IL (1) IL240131B (cg-RX-API-DMAC7.html)
JO (1) JO3494B1 (cg-RX-API-DMAC7.html)
LT (1) LT2958907T (cg-RX-API-DMAC7.html)
MA (1) MA38325B1 (cg-RX-API-DMAC7.html)
ME (1) ME03061B (cg-RX-API-DMAC7.html)
MX (1) MX359471B (cg-RX-API-DMAC7.html)
MY (1) MY174888A (cg-RX-API-DMAC7.html)
NI (1) NI201500106A (cg-RX-API-DMAC7.html)
NO (1) NO3077717T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ710385A (cg-RX-API-DMAC7.html)
PE (1) PE20151428A1 (cg-RX-API-DMAC7.html)
PH (1) PH12015501832A1 (cg-RX-API-DMAC7.html)
PL (1) PL2958907T3 (cg-RX-API-DMAC7.html)
PT (1) PT2958907T (cg-RX-API-DMAC7.html)
RS (1) RS57106B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201505697VA (cg-RX-API-DMAC7.html)
SI (1) SI2958907T1 (cg-RX-API-DMAC7.html)
TN (1) TN2015000323A1 (cg-RX-API-DMAC7.html)
TR (1) TR201806882T4 (cg-RX-API-DMAC7.html)
TW (1) TWI612040B (cg-RX-API-DMAC7.html)
UY (1) UY35334A (cg-RX-API-DMAC7.html)
WO (1) WO2014130310A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201505305B (cg-RX-API-DMAC7.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2958907T (pt) 2013-02-19 2018-03-23 Novartis Ag Derivados de benzofiofeno e suas composições como degradadores seletivos de recetores de estrogénios
KR20170118687A (ko) * 2015-02-19 2017-10-25 제이엔씨 주식회사 벤조티오펜을 가지는 액정성 화합물, 액정 조성물 및 액정 표시 소자
TWI708770B (zh) * 2015-06-08 2020-11-01 日商捷恩智股份有限公司 具有苯并噻吩的液晶性化合物、液晶組成物及液晶顯示元件
EP3386968B1 (en) 2015-12-09 2025-04-02 The Board of Trustees of the University of Illinois Benzothiophene-based selective estrogen receptor downregulator compounds
KR20220071293A (ko) 2016-04-01 2022-05-31 리커리엄 아이피 홀딩스, 엘엘씨 에스트로겐 수용체 조절제
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
AU2018205262A1 (en) * 2017-01-06 2019-07-11 G1 Therapeutics, Inc. Combination therapy for the treatment of cancer
WO2018148576A1 (en) * 2017-02-10 2018-08-16 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators
WO2019097426A1 (en) 2017-11-16 2019-05-23 Novartis Ag Pharmaceutical combination comprising lsz102 and ribociclib
US20200277378A1 (en) 2017-11-16 2020-09-03 Novartis Ag Combination therapies
JP2021504384A (ja) * 2017-12-01 2021-02-15 ノバルティス アーゲー Ｌｓｚ１０２及びアルペリシブを含む医薬品の組合せ
SG11202006942WA (en) 2018-01-22 2020-08-28 Radius Pharmaceuticals Inc Estrogen receptor-modulating compounds
CN112041307B (zh) * 2018-02-06 2024-02-09 伊利诺伊大学评议会 作为选择性雌激素受体降解剂的取代的苯并噻吩类似物
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
EP3836916A1 (en) * 2018-08-16 2021-06-23 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators to treat medical disorders
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
ES2982474T3 (es) 2019-02-15 2024-10-16 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos
JP7483732B2 (ja) 2019-02-15 2024-05-15 ノバルティス アーゲー ３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
AU2020279230A1 (en) 2019-05-20 2021-12-02 Les Laboratoires Servier Mcl-1 inhibitor antibody-drug conjugates and methods of use
KR20220044528A (ko) 2019-08-06 2022-04-08 리커리엄 아이피 홀딩스, 엘엘씨 돌연변이체를 치료하기 위한 에스트로겐 수용체 조절제
JP2023507190A (ja) 2019-12-20 2023-02-21 ノバルティス アーゲー 増殖性疾患を治療するための抗ＴＧＦβ抗体及びチェックポイント阻害薬の使用
CN111057065B (zh) * 2019-12-24 2021-04-23 沈阳药科大学 噻吩并嘧啶类化合物的制备方法和用途
CN111646972B (zh) * 2020-06-12 2021-06-29 上海皓元医药股份有限公司 一种选择性雌激素受体降解剂及其中间体的制备方法
US20230321067A1 (en) 2020-06-23 2023-10-12 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2022010937A1 (en) * 2020-07-06 2022-01-13 Tactogen Inc Advantageous benzothiophene compositions for mental disorders or enhancement
EP4188549A1 (en) 2020-08-03 2023-06-07 Novartis AG Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP4251208A1 (en) 2020-11-24 2023-10-04 Novartis AG Mcl-1 inhibitor antibody-drug conjugates and methods of use
EP4251648A2 (en) 2020-11-24 2023-10-04 Novartis AG Anti-cd48 antibodies, antibody drug conjugates, and uses thereof
JP2024502270A (ja) 2020-12-23 2024-01-18 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー エストロゲン受容体調節薬
WO2022169780A1 (en) 2021-02-02 2022-08-11 Les Laboratoires Servier Selective bcl-xl protac compounds and methods of use
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
CN116265458A (zh) * 2021-12-17 2023-06-20 中国科学院上海药物研究所 苯并噻吩类衍生物、及其制备方法和用途
GB2617173B (en) 2022-03-31 2024-11-20 Iceye Oy Detecting and suppressing ambiguities in synthetic aperture radar data and images
CN119604315A (zh) 2022-05-20 2025-03-11 诺华股份有限公司 Epha2 bcl-xl抑制剂抗体-药物缀合物及其使用方法
AR129382A1 (es) 2022-05-20 2024-08-21 Novartis Ag Conjugados de anticuerpo-fármaco inhibidores de bcl-xl y met y sus métodos de uso
CN115710248B (zh) * 2022-11-18 2024-06-21 南京中医药大学 新型选择性雌激素受体下调剂化合物、制备方法及用途
WO2024189481A1 (en) 2023-03-10 2024-09-19 Novartis Ag Panras inhibitor antibody-drug conjugates and methods of use thereof
WO2025111450A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd74 antibody-drug conjugates and methods of use thereof
WO2025215536A1 (en) 2024-04-10 2025-10-16 Novartis Ag Macrocyclic panras inhibitors for the treatment of cancer

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH445129A (fr) 1964-04-29 1967-10-15 Nestle Sa Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3453257A (en) 1967-02-13 1969-07-01 Corn Products Co Cyclodextrin with cationic properties
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US3453259A (en) 1967-03-22 1969-07-01 Corn Products Co Cyclodextrin polyol ethers and their oxidation products
JPS6041077B2 (ja) 1976-09-06 1985-09-13 喜徳 喜谷 １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
ZA822247B (en) * 1981-04-03 1983-11-30 Lilly Co Eli Benzothiophene compounds and process for preparing them
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US5266573A (en) 1989-08-07 1993-11-30 Elf Sanofi Trifluoromethylphenyltetrahydropyridines for the treatment and/or prophylaxis of intestinal motility disorders
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US6562862B1 (en) * 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
US5589482A (en) 1994-12-14 1996-12-31 Pfizer Inc. Benzo-thiophene estrogen agonists to treat prostatic hyperplasia
IL117276A (en) 1995-02-28 2001-10-31 Lilly Co Eli Benzothiophene compounds, their preparation and pharmaceutical compositions comprising them
US5510357A (en) 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
US5998441A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US6417199B1 (en) 1995-03-10 2002-07-09 Eli Lilly And Company 3-benzyl-benzothiophenes
WO1997001549A1 (en) 1995-06-26 1997-01-16 Eli Lilly And Company Benzothiophene compounds
US5731342A (en) 1996-02-22 1998-03-24 Eli Lilly And Company Benzothiophenes, formulations containing same, and methods
US5827876A (en) * 1996-04-09 1998-10-27 American Home Products Corporation Inhibition of bone loss by 3-(4-acrylamidobenzoyl) benzo b!-thiophenes
US5886025A (en) 1997-03-06 1999-03-23 Baylor University Anti-mitotic agents which inhibit tubulin polymerization
ZA982818B (en) 1997-04-09 1999-10-04 Lilly Co Eli Prevention of breast cancer using selective estrogen receptor modulators.
ZA982819B (en) 1997-04-09 1999-10-04 Lilly Co Eli Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogn receptor modulators.
ZA982877B (en) 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
US6166069A (en) 1998-05-12 2000-12-26 American Home Products Corporation Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
AU3791799A (en) 1998-05-12 1999-11-29 American Home Products Corporation Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
MXPA02007603A (es) 2000-03-09 2003-02-24 Aventis Pharma Gmbh Usos terapeuticos de mediadores ppar.
US7091240B2 (en) 2000-03-10 2006-08-15 Oxigene, Inc. Tubulin binding ligands and corresponding prodrug constructs
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7425565B2 (en) 2002-05-09 2008-09-16 Cedars-Sinai Medical Center Use of benzothiopenes to treat and prevent prostate cancer
EP1478648B1 (en) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
DE60321141D1 (en) 2002-03-05 2008-07-03 Axys Pharm Inc Cathepsin-cystein-protease-hemmer
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
CA2490580C (en) 2002-07-22 2012-12-11 Eli Lilly And Company Selective estrogen receptor modulators containing a naphthalene group
WO2005000834A1 (en) 2003-06-10 2005-01-06 Eli Lilly And Company Pentafluoroalkanesulfinyl naphthalenes and related estrogen receptor modulators
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
EP1709022A1 (en) 2004-01-22 2006-10-11 Eli Lilly And Company Selective estrogen receptor modulators
ATE448215T1 (de) * 2004-01-22 2009-11-15 Lilly Co Eli Selektive östrogen-rezeptor-modulatoren
WO2005073190A1 (en) 2004-01-29 2005-08-11 Eli Lilly And Company Selective estrogen receptor modulators
KR101225018B1 (ko) 2004-09-02 2013-01-23 쿠리스 인코퍼레이션 헤지호그 신호전달에 대한 피리딜 억제제
EP1853590A1 (en) 2005-03-03 2007-11-14 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EA200970863A1 (ru) 2007-03-16 2010-02-26 Эли Лилли Энд Компани Способ и промежуточные соединения для получения арзоксифена
US20090069380A1 (en) 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched aroxifene
JP5658565B2 (ja) 2007-09-12 2015-01-28 ジェネンテック， インコーポレイテッド ホスホイノシチド３−キナーゼ阻害剤化合物と化学療法剤との組合せ、および使用方法
CN101909631B (zh) 2007-10-25 2012-09-12 健泰科生物技术公司 制备噻吩并嘧啶化合物的方法
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
CN102477033A (zh) * 2010-11-23 2012-05-30 苏州波锐生物医药科技有限公司 苯并噻酚类化合物及其在制备预防和/或治疗乳腺癌骨质疏松症药物中的用途
ES2586908T3 (es) 2010-12-24 2016-10-19 Merck Sharp & Dohme B.V. Derivados de azetidina N-sustituidos
PT2958907T (pt) 2013-02-19 2018-03-23 Novartis Ag Derivados de benzofiofeno e suas composições como degradadores seletivos de recetores de estrogénios

Also Published As

Publication number Publication date
ME03061B (me) 2019-01-20
CA2899030C (en) 2021-03-09
GT201500233A (es) 2016-01-21
CR20150424A (es) 2015-10-19
BR112015018882A2 (pt) 2017-07-18
ZA201505305B (en) 2016-09-28
DOP2015000202A (es) 2015-11-30
CL2015002098A1 (es) 2015-11-13
DK2958907T3 (en) 2018-06-06
KR102279999B1 (ko) 2021-07-22
JP2016509022A (ja) 2016-03-24
TR201806882T4 (tr) 2018-06-21
CY1120155T1 (el) 2018-12-12
IL240131A0 (en) 2015-09-24
EP3360870A1 (en) 2018-08-15
HK1211941A1 (en) 2016-06-03
TW201443034A (zh) 2014-11-16
MA38325A2 (fr) 2016-12-30
CN105008343B (zh) 2017-12-08
PH12015501832B1 (en) 2015-11-09
US20140235660A1 (en) 2014-08-21
BR112015018882B1 (pt) 2021-09-14
LT2958907T (lt) 2018-04-25
PE20151428A1 (es) 2015-09-24
NZ710385A (en) 2016-10-28
EA201591537A1 (ru) 2015-12-30
NI201500106A (es) 2015-10-20
PL2958907T3 (pl) 2018-07-31
CU20150090A7 (es) 2016-04-25
US9931317B2 (en) 2018-04-03
MY174888A (en) 2020-05-20
EA028032B1 (ru) 2017-09-29
TN2015000323A1 (en) 2017-01-03
PT2958907T (pt) 2018-03-23
IL240131B (en) 2018-11-29
AP2015008618A0 (en) 2015-07-31
MA38325B1 (fr) 2019-03-29
MX2015010752A (es) 2015-11-30
MX359471B (es) 2018-09-28
AU2014219283C1 (en) 2016-10-27
US20180169063A1 (en) 2018-06-21
PH12015501832A1 (en) 2015-11-09
US9321746B2 (en) 2016-04-26
GEP201706638B (en) 2017-03-10
US10058534B2 (en) 2018-08-28
US20160184265A1 (en) 2016-06-30
CN105008343A (zh) 2015-10-28
RS57106B1 (sr) 2018-06-29
TWI612040B (zh) 2018-01-21
CU24337B1 (es) 2018-04-03
SG11201505697VA (en) 2015-09-29
US20150361065A1 (en) 2015-12-17
HK1251227A1 (en) 2019-01-25
EP2958907A1 (en) 2015-12-30
WO2014130310A1 (en) 2014-08-28
AR094704A1 (es) 2015-08-19
AU2014219283A1 (en) 2015-08-13
US20170112805A1 (en) 2017-04-27
KR20150119385A (ko) 2015-10-23
AU2014219283B2 (en) 2015-10-29
JP6364028B2 (ja) 2018-07-25
NO3077717T3 (cg-RX-API-DMAC7.html) 2018-07-21
CA2899030A1 (en) 2014-08-28
US8877801B2 (en) 2014-11-04
HRP20180816T1 (hr) 2018-06-29
MA38325A3 (fr) 2018-05-31
US9561211B2 (en) 2017-02-07
EP2958907B1 (en) 2018-02-28
UY35334A (es) 2014-09-30
JO3494B1 (ar) 2020-07-05
HUE039052T2 (hu) 2018-12-28
SI2958907T1 (en) 2018-05-31

Similar Documents

Publication Publication Date Title
ES2671516T3 (es) Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno
JP6465840B2 (ja) エストロゲン受容体モジュレーターおよびその用途
ES2710556T3 (es) Compuesto inhibidor de Trk
CN103189361B (zh) 雌激素受体调节剂及其用途
CN101641013B (zh) 核受体结合剂
JP6100439B2 (ja) アンドロゲン受容体調節薬のエステル誘導体およびそれらの使用のための方法
Morales et al. Synthetic cannabinoid quinones: Preparation, in vitro antiproliferative effects and in vivo prostate antitumor activity
ES2627316T3 (es) Síntesis del compuesto de polihidroxi benzopirano cetona y efecto antitumoral del mismo
TWI639585B (zh) 非類固醇抗雄激素及具有吡啶部份的選擇性雄激素受體調節劑
Shi et al. Novel anti-prostate cancer curcumin analogues that enhance androgen receptor degradation activity
ES2606043T3 (es) Derivados de biarilo como moduladores de nAChR
PH12015501738B1 (en) Androgen receptor modulators and uses thereof
BR112014019478A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmacologicamente aceitável do mesmo, formulação inibidor do canal de sódio, métodos para tratamento e/ou prevenção de dor e de uma doença.
RU2369614C2 (ru) НОВЫЕ ИНГИБИТОРЫ 17β-ГИДРОКСИСТЕРОИД-ДЕГИДРОГЕНАЗЫ ТИПА I
ES2925102T3 (es) Nuevo derivado de arileteno y composición farmacéutica que lo contiene como ingrediente activo
RU2007120454A (ru) Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3
CA2924062A1 (en) Therapeutics targeting truncated adenomatous polyposis coli (apc) proteins
JP2009516747A5 (cg-RX-API-DMAC7.html)
TWI226831B (en) Pharmaceutical composition for ameliorating an undesirable anxiety state in a mammal
ES2358931T3 (es) Uso de un inhibidor de quinasa p38 para el tratamiento de trastornos psiquiatricos.
ES2919557T3 (es) Nuevo derivado de aril etano y composición farmacéutica que lo contiene como ingrediente activo
CA2501556A1 (en) Remedy for hormone-dependent cancer
ES2701810T3 (es) Compuestos de triazol y su uso como moduladores de gamma-secretasa
JP6205373B2 (ja) Ｎｄｇａ誘導体およびソラフェニブを含む組成物、ならびにがんの処置におけるこれらの使用
TW202135818A (zh) 組合